Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Exp Med
Main Authors: Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam
פורמט: Artigo
שפה:Inglês
יצא לאור: Rockefeller University Press 2018
נושאים:
Research Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6028519/
https://ncbi.nlm.nih.gov/pubmed/29880484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171960
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים